Crisil rates Sun Pharma debt AAA. Sun Pharma stock is valued at INR 4.2 trillion

Published on 10/16/2026 at 11:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The board approved an INR 100.0 billion debt plan on October 12, 2026. Sun Pharma stock saw Q1 fiscal 2027 revenue reach INR 153.00 billion.

Debt funding and upcoming dates

Crisil assigned AAA ratings to Sun Pharma's proposed debt on October 13, 2026.
First-quarter fiscal 2027 revenue reached INR 153.00 billion on June 30, 2026.
Sun Pharma stock has a market capitalization of INR 4.2 trillion as of October 16, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma received a AAA rating for proposed debt after approving an INR 100.0 billion borrowing plan on October 12, 2026, according to Business Standard. For investors, the financing framework matters because the company is preparing funding arrangements linked to its proposed Organon acquisition.

Three dates frame the financing

Business Standard reported three relevant milestones: Sun Pharma agreed to extend US Medicaid pricing terms on September 1, 2026, approved debt issuance of up to INR 100.0 billion on October 12, 2026, and received Crisil ratings of Crisil AAA/Stable for the proposed debentures on October 13, 2026.

The proposed borrowing sits alongside a broader acquisition funding structure. In its October 1, 2026 postal-ballot notice, Sun Pharmaceutical Industries described proposed approvals for borrowing limits of INR 700.0 billion and financing facilities of up to USD 12.0 billion connected with the Organon transaction.

What does the financing mean for margins?

The operating picture remains profitable but includes a clear pressure point. First-quarter fiscal 2027 revenue reached INR 153.00 billion, up 10.50 percent year over year, while operating profit was INR 42.96 billion, according to the standardized financial statement for the period ended June 30, 2026.

Business Standard reported first-quarter operating income of INR 153.00 billion and an operating margin of 29.00 percent, down from 31.10 percent in the comparable period. The contrast is important: revenue growth is positive, but integration funding and weaker US generics could keep margins central to the next results discussion.

Results and voting dates ahead

The next scheduled financial-results date is October 30, 2026, according to NSE. The postal-ballot process is scheduled to close on October 31, 2026, with results due on or before November 3, 2026, under the company's October 2026 notice.

Stock value and operating risk

Sun Pharma was trading at INR 1,755.20 on NSE on October 16, 2026 at 2:41 p.m. IST. Its market capitalization was INR 4.2 trillion, while the 52-week range stood at INR 1,583.70 to INR 2,046.90. The valuation gives the financing decision a direct market dimension, while the upcoming results will show whether first-quarter growth can offset margin and US pricing pressure.

The latest quote and market data place Sun Pharma within the Nifty 50 and identify pharmaceuticals as its basic industry. The company remains one of India's largest drugmakers, with India growth and specialty medicines balancing pressure in US generics.